Cefiderocol for resistant Gram negatives: linking in vitro activity with clinical effectiveness

In this Commentary, we discuss the main findings of a systematic review with meta-analysis of in vitro susceptibility data for cefiderocol against gram-negative bacilli. We then put these results in context of the questions Clinicians are faced when considering prescribing cefiderocol. We also briefly review the evidence on which cefiderocol use is based, with the aid of a summary table of clinical studies published over the last 2 years. Our Commentary briefly touches on when cefiderocol can be an option, and whether resistance data should be a consideration at the patient bedside.